WHO backs Regeneron drug for COVID-19, urges action on price
Al Jazeera
The World Health Organisation (WHO) has added the Regeneron antibody drug cocktail – casirivimab and imdevimab – to its list of treatments for people with COVID-19, urging the manufacturer to reduce the price and ensure equitable distribution.
Clinical studies showed the drug combination was effective in patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies, the WHO said in a statement on Friday.
It is the first drug against COVID-19 the WHO has recommended for use in non-severe high-risk patients to reduce the chances of the disease progressing.
More Related News